Thirty-one patients with advanced inoperable squamous carcinoma of the mouth were treated in a pilot study with misonidazole (2.0 gm/m2) with each of six fractions of 6.0 Gy in hyperbaric oxygen at 3 ATA. The one and two year disease free survival was 48 and 26%, respectively. A prospective randomized trial is now being conducted comparing this regimen with 63.0 Gy in 30 fractions in 38 days in air. One hundred-fourteen patients have been entered; 91 are available for analysis at six months or more. The preliminary results at 6 and 12 months favor the combination of sensitizers. There is no added toxicity.
Sealy, Cridland, , , , , , , (1984). The treatment of locally advanced head and neck cancer with misonidazole, hyperbaric oxygen and irradiation: an interim report. International journal of radiation oncology, biology, physics, 1984 Sep;10(9):1721-3. https://www.ncbi.nlm.nih.gov/pubmed/6384161